BOBULSKY SUSAN 4

What Happened

Susan Bobulsky, Chief Commercial Officer of Adaptive Biotechnologies (ADPT), sold 5,000 shares in an open-market transaction on June 25, 2026. The shares were sold at $20.50 per share for a total proceeds of $102,500. This was a sale (not a purchase), which is commonly routine insider selling rather than a direct bullish signal.

Key Details

• Transaction date and price: 2026-06-25, 5,000 shares at $20.50 each.
• Total value: $102,500.
• Transaction type: Sale (open market/private sale as reported).
• Shares owned after transaction: Not specified in the provided filing excerpt — check the full Form 4 for post-transaction ownership.
• Footnote: Trade was executed under a Rule 10b5-1 trading plan adopted by Ms. Bobulsky on December 16, 2025.
• Filing timeliness: Form 4 filed on 2026-06-29 for a 2026-06-25 trade (filed within the normal two-business-day reporting window).

Context

A 10b5-1 plan allows insiders to execute pre-scheduled trades regardless of subsequent company developments; such sales are often routine and do not necessarily reflect the insider’s current view of the company. For a fuller picture, compare this sale to recent insider activity and the insider’s remaining holdings shown in the complete Form 4.